Peptides · Peptide comparison
Retatrutide vs Setmelanotide
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
Targeted MC4R agonist for rare genetic obesity caused by melanocortin pathway defects
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Weight Loss Power
Metabolic Health
Appetite Control
Weight Management
Quality of Life
Technical data
Compound specifications
Retatrutide
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731 g/mol
- Half-life
- ~6 days (allows once-weekly dosing)
- Bioavailability
- High via subcutaneous injection
- CAS number
- 2381089-83-2
Setmelanotide
- Molecular formula
- C49H68N18O9S2
- Molecular weight
- 1,117.3 Da
- Half-life
- ~11 hours
- Bioavailability
- ~79% subcutaneous bioavailability
- CAS number
- 920014-72-8
Protocols
Dosing compared
Retatrutide
Subcutaneous
- Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
- Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
- Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Setmelanotide
Subcutaneous
- First 2 weeks2 mgOnce daily · First 2 weeksFDA Imcivree starting dose for BBS or POMC/PCSK1/LEPR-deficiency obesity in patients 2 years and older; injected on waking [6]. (Acquired hypothalamic obesity starts lower at 0.5 mg daily.)
- Ongoing maintenance3 mgOnce daily · Ongoing maintenanceRecommended maintenance/maximum dose after tolerating 2 mg for 2 weeks; first approval and pivotal trials [1][6]. Effective for MC4R-pathway and hypothalamic obesity [2][3].
Applications
Best suited for
Retatrutide
- Significant Obesity Management
- If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
- Type 2 Diabetes with Obesity
- Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
- Metabolic Syndrome Warriors
- If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
- Fatty Liver Disease (MASLD)
- Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Setmelanotide
- Treating obesity caused by confirmed POMC deficiency mutations
- Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][6].
- Managing obesity from PCSK1 or LEPR genetic defects
- Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][6].
- Reducing hyperphagia and body weight in Bardet-Biedl syndrome
- Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
- Addressing early-onset severe obesity with identified melanocortin pathway mutations
- Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2].
Safety profile
Side effects
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Setmelanotide
Common
- Skin Hyperpigmentation
- Injection Site Reactions
- Nausea
- Diarrhea
Uncommon
- Hair Color Darkening and Nevus Changes
Serious
- Depression and Suicidal Ideation
Research status
Safety & evidence
Retatrutide
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Setmelanotide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations. The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) [6] due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity. [6] Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients [6].
Contraindications
- Known hypersensitivity to setmelanotide or any excipients [6]
- Obesity not caused by POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome, or acquired hypothalamic obesity [6]
- Suspected POMC, PCSK1, or LEPR deficiency where the gene variants are classified as benign or likely benign (BBS and acquired hypothalamic obesity need no genetic test) [6]
Decision guide
Which is right for you?
Retatrutide
Choose Retatrutide if…
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization
Setmelanotide
Choose Setmelanotide if…
- Treating obesity caused by confirmed POMC deficiency mutations
- Managing obesity from PCSK1 or LEPR genetic defects
- Reducing hyperphagia and body weight in Bardet-Biedl syndrome
- Addressing early-onset severe obesity with identified melanocortin pathway mutations